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Abstract The anti-angiogenic activity of chemotherapy
is both dose- and schedule-dependent. While conventional
maximum tolerated dose (MTD) chemotherapy exerts only
mild and reversible anti-angiogenic effects, low-dose
metronomic (LDM) chemotherapy was developed to spe-
cifically target tumour angiogenesis. However, the long-
term effects of either MTD or LDM chemotherapy on
vascular endothelial cells have never been investigated.
Here, we demonstrated that repeated exposure to MTD and
LDM chemotherapy differentially impact on the angio-
genic potential and chemosensitivity of immortalized
endothelial cells. Repeated MTD vinblastine treatment of
vascular endothelial cells led to an increased proliferation
rate and resistance to paclitaxel. In contrast, repeated LDM
treatment with vinblastine or etoposide impaired the
angiogenic potential of endothelial cells and increased their
chemosensitivity. This effect was associated with a sig-
nificant decrease in bII- and bIII-tubulin expression.
Functional analysis using siRNA showed that silencing the
expression of bIII-tubulin in endothelial cells significantly
decreased their capacity to form vascular structures and
increased their sensitivity to the anti-angiogenic and vas-
cular-disrupting effects of chemotherapy, whereas silenc-
ing bII-tubulin expression had no effect. Collectively our
results show that LDM chemotherapy impairs the angio-
genic potential of endothelial cells while increasing their
chemosensitivity—an effect at least in part mediated by the
down-regulation of bIII-tubulin expression. Furthermore,
our study suggests that bIII-tubulin represents an attractive
therapeutic target to increase the anti-angiogenic effects of
chemotherapy and overall anti-tumour efficacy.
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The discovery of the central role played by tumour angi-
ogenesis in cancer progression and metastasis has not only
led to the development of novel anti-cancer drugs specifi-
cally targeting this key biological process but also insti-
gated the re-examination of conventional chemotherapy
agents. A number of studies thus revealed that many of the
chemotherapeutic drugs commonly used in the clinic are
effective at treating cancer because they can affect both the
cancer cells and the tumour vasculature [1–3]. This led to
the development of novel treatment modalities aimed at
promoting the anti-angiogenic activity of chemotherapy.
These new treatment schedules, called metronomic
chemotherapy or metronomic scheduling of anti-cancer
treatment (MSAT) [4–6], are based on more frequent
administration of chemotherapeutic drugs at relatively low
dose, as compared to conventional chemotherapy, and with
no prolonged drug-free interval. Following initial demon-
stration of efficacy in pre-clinical models [1, 7], metro-
nomic chemotherapy has shown promising results in a
number of clinical applications (reviewed in [5, 6]), such as
advanced breast cancer in adults [8, 9] or recurrent
medulloblastoma in children [10]. Furthermore, the effi-
cacy of metronomic chemotherapy is currently investigated
in several phase II and III clinical trials worldwide in a
variety of human malignancies (http//:clinicaltrials.gov).
Despite accumulating evidence of clinical benefits, the
complex and multi-faceted mechanism of action of met-
ronomic chemotherapy has only been partially unveiled
and warrants further investigation. One of the initial
rationales for the development of anti-angiogenic therapies
in general, and metronomic chemotherapy in particular,
was based on the idea that, unlike cancer cells, vascular
endothelial cells are genetically stable and thus less likely
to acquire drug resistance [1, 11, 12]. However, accumu-
lating evidence suggests that this hypothesis is, at least in
part, incorrect. Endothelial cells isolated from tumour
blood vessels were found to display tumour-specific
genetic abnormalities [13–15]. In addition, studies have
shown that tumour endothelial cells can be intrinsically
resistant to chemotherapeutic drugs, such as adriamycin
and temozolomide [16, 17], and even acquire drug resis-
tance through VEGF-induced up-regulation of MDR1
expression [18]. The long-term effects of chemotherapy on
vascular endothelial cells remains however unexplored.
Recent studies revealed that chemotherapy dosing
schedule strongly influences drug resistance development
in cancer cells. Weekly docetaxel treatment was found to
induce the up-regulation of a number of genes involved in
drug resistance, including TUBB3 (i.e. the gene encoding
b-III tubulin) and ATP-binding cassette (ABC) transporters
ABCB1 and ABCC10, in xenografted ovarian tumours
whereas continuous docetaxel treatment did not [19].
Furthermore, Kerbel and colleagues demonstrated that
extended low-dose metronomic (LDM) cyclophosphamide
therapy could lead to drug resistance in prostate cancer
cells in vivo but these cells retained sensitivity to maxi-
mum-tolerated dose (MTD) cyclophosphamide [20]. This
strongly suggests that resistance to LDM chemotherapy in
cancer cells imparts distinct mechanisms of resistance to
MTD chemotherapy. Here, we hypothesized that, similarly
to what was reported in tumour cells, repeated exposure to
either LDM or MTD chemotherapy would differentially
impact on the angiogenic potential and chemosensitivity of
endothelial cells, through modulation of the expression of
genes involved in drug resistance, such as ABC trans-
porters and b-tubulin isotypes.
Materials and methods
Cell culture
BMH29L cells are bone marrow-derived endothelial cells
(BMECs) that were immortalized by ectopic expression of
human telomerase reverse transcriptase [21]. They were
grown in Medium 199 (Invitrogen) containing 10 % heat-
inactivated Fetal Calf Serum (FCS), 5 % male human
serum, AB only (Sigma-Aldrich, Castle Hill, Australia),
1 % penicillin and streptomycin, 1 % heparin, 5 ng/mL
recombinant human FGFb (fibroblast growth factor b;
Sigma-Aldrich) and 20 lg/mL Endothelial Cell Growth
Factor (Roche, Dee Why, Australia). HMEC-1 (Human
Microvascular Endothelial Cell line 1) cells were originally
developed by Prof Ades [22] and obtained from the Cell
Culture Laboratory in the Hoˆpital de la Conception
(Assistance Publique Hoˆpitaux de Marseille, Marseille,
France). They were grown in MCDB-131 medium (Invit-
rogen, Mount Waverley, Australia) containing 10 % heat-
inactivated FCS, 2 mM L-glutamine, 1 % penicillin and
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streptomycin, 1 lg/mL hydrocortisone and 10 ng/mL epi-
thelial growth factor (BioScientific, Gymea, Australia).
Both cell lines were routinely maintained in culture on
0.1 % gelatin-coated flasks at 37 C and 5 % CO2. Cell
lines were regularly screened and are free from myco-
plasma contamination.
Long-term drug treatment
BMH29L cells were incubated with vinblastine (VLB) or
etoposide (VP16) following a maximum-tolerated dose
(MTD) conventional schedule or a low-dose metronomic
(LDM) schedule for a total duration of 100 days (Online
Resource 1). In the MTD schedule, BMH29L cells were
treated every 2 weeks for a total of 7 courses with drug-
free medium (Ctrl-MTD) or containing VLB or VP16 at the
IC80 for cell proliferation (i.e. 20 nM and 50 lM of VLB
and VP16, respectively). In the LDM schedule, BMH29L
cells were treated 5 days a week for a total of 14 courses
with drug-free medium (Ctrl-LDM) or containing VLB or
VP16 at the highest non-toxic concentration (i.e. 1 nM and
0.5 lM of VLB and VP16, respectively). This led to the
establishment of 6 new BMH29L subclones: Ctrl-LDM,
Ctrl-MTD, VLB-LDM, VLB-MTD, VP16-LDM and VP16-
MTD. These subclones were cryopreserved at the end of
the long-term treatment and not kept in culture for more
than 1 month for all subsequent experiments.
Doubling time and growth inhibition assay
Following long-term drug treatment, BMH29L subclones
were seeded onto 6-well plates at a cell density of 20,000
cells/well and counted every 24 h for 4 days using the
trypan blue exclusion method. Doubling times were
determined by mathematical regression using GraphPad
Prism 4 software (GraphPad Software Inc, La Jolla, CA).
Growth inhibition assays were performed as previously
described [23]. Briefly, cells were seeded at 1,500 cells/
well (BMH29L) or 3,750 cells/well (HMEC-1) in 96-well
gelatin-coated plates. After 24 h, cells were treated with a
range of concentrations of chemotherapeutic drugs and
after 72 h drug incubation, metabolic activity was detected
by addition of Alamar blue and spectrophotometric anal-
ysis. Cell proliferation was determined and expressed as a
percentage of untreated control cells. The determination of
IC50 and IC80 values was performed by point-to-point fit
spline analysis using GraphPad Prism 4 software.
Quantitative RT-PCR
The expression of ABC transporters ABCB1, ABCC1,
ABCC2 and ABCC10 and b-tubulin genes TUBB, TUBB2A
and TUBB3 was examined in BMH29L subclones using
real-time quantitative RT-PCR, as previously described [24,
25]. Total RNA was extracted and DNAse treated using the
Qiagen Mini RNeasy kit according to the manufacturer
instructions (Qiagen, Doncaster, Australia). cDNA synthesis
was performed using High capacity cDNA reverse tran-
scription kit with RNAse inhibitor according to the manu-
facturer instructions (Applied Biosystem, Melbourne,
Australia). Real time PCR was run on 7900HT Fast Real-
Time PCR system using either Taqman gene expression
assays (Applied Biosystems) for ABCB1 (Hs00184500),
ABCC1 (Hs01561503), ABCC10 (Hs00375716) and
endogenous control HPRT1 (4326321E) or Power SYBR
green (Applied Biosystems) for TUBB (QT00089775),
TUBB2A (QT01677326), TUBB3 (QT00083713) and
endogenous control GAPDH (QT01192646). ABCC2 for-
ward and reverse primer sequences were 50-AGAGAACA
GCTTTCGTCGAACAC-30 and 50-CATTCCGAGTTTTC
AAGGAGTTTC-30, respectively. ABCC2 probe sequence
was ACCTAGAACTGCGGCTA. Gene expression levels
were determined using the DDCt method, normalized to
the HPRT1 control for ABC transporters and the GAPDH
control for b-tubulin genes, and expressed relative to a
calibrator [26].
Radiolabelled drug accumulation assay
For drug accumulation studies, BMH29L subclones, see-
ded in 12-well plates, were incubated for 4 h at 37 C with
[3H]-vincristine (15.8 Ci/mmol; final concentration 50 nM)
in presence or absence of 10 lM verapamil. Cells were
then washed thrice with ice-cold PBS to eliminate the
extracellular tritiated drug and lysed in 0.5 M NaOH.
Intracellular [3H]-vincristine concentration was determined
by b-scintillation counting and normalized to protein con-
tent, as determined by BCA assay [27].
In vitro MatrigelTM assay
MatrigelTM (BD Biosciences, North Ryde, Australia)
assay was used to determine the effects of repeated
exposure to chemotherapy and bII and bIII tubulin
knockdown on the angiogenic potential and chemosensi-
tivity of endothelial cells, as previously described [23].
For the anti-angiogenesis analysis, cells were treated with
different drug solutions 20 min after seeding on Matrigel
and photographs were taken after 8 h drug incubation
using the 5X objective of an Axiovert 200 M fluorescent
microscope coupled to an AxioCamMR3 camera driven
by the AxioVision 4.7 software (Carl Zeiss, North Ryde,
Australia). For the vascular-disruption analysis, cells were
allowed to undergo morphogenesis and form capillary-like
structures for 6 h before drug treatment was initiated.
Photographs were then taken using the same microscope
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device after 2 h drug incubation. The anti-angiogenic and
vascular-disrupting effects were then quantitatively eval-
uated by measuring the total surface area of capillary
tubes formed in at least 10 view fields per well using
AxioVision 4.7 software.
Gene silencing by small interfering RNA
bII- and bIII-tubulin gene expression were silenced in
endothelial cells using siRNA sequences whose potency
and specificity have been validated previously [28, 29] and
obtained from Dharmacon (Thermo Fisher Scientific,
Scoresby, Australia) and Qiagen (Qiagen), respectively.
The optimum amount of siRNA was determined to be
200 pmol (data not shown) and was used in all subsequent
experiments. A non-silencing control siRNA, which has no
sequence homology to any known human gene sequence,
was used as a negative control in all experiments (Qiagen).
Cells were transfected using the Nucleofector II device
(Lonza, Mount Waverley, Australia) as previously descri-
bed [30]. Briefly, HMEC-1 and BMH29L cells were
resuspended in nucleofector solution R and V, respec-
tively, and transfected with siRNA using specific nucleo-
fector programs (T-016 and S-003 for HMEC-1 and
BMH29L, respectively). In all subsequent experiments,
drug treatment was initiated 72 h after siRNA transfec-
tion—when the knockdown of the targeted gene was the
most effective.
Western blotting analysis
Total cellular proteins from endothelial cells (10–15 lg)
were resolved on 12 % SDS-PAGE before electrotransfer
onto nitrocellulose membrane. Immunoblotting was done
using antibodies directed against bI-tubulin (clone SAP
4G5; Abcam), bII-tubulin (clone 7B9; Chemicon), bIII-
tubulin (clone TUJ1; Chemicon), bIV-tubulin (clone ONS
1A6; Sigma-Aldrich), total b-tubulin (clone TUB 2.1;
Sigma-Aldrich) and glyceraldehyde-3-phosphate dehydro-
genase (GADPH; Abcam). The membranes were then
incubated with horseradish peroxidase–conjugated IgG
secondary antibodies, and protein was detected with ECL
Plus (GE Healthcare Life Sciences). The blots were scan-
ned and densitometric analysis performed as previously
described [31].
Statistical analysis
All experiments were performed at least in triplicate.
Statistical significance was determined using two-sided
student’s t-test in the GraphPad Prism 4 software (Graph-
Pad Software, Inc).
Results
Conventional and metronomic chemotherapy
differentially impact on the angiogenic potential
of vascular endothelial cells
Bone marrow-derived endothelial cells immortalized by
ectopic expression of human telomerase reverse transcrip-
tase [21] were treated for 100 days with vinblastine (VLB) or
etoposide (VP16) following a low-dose metronomic (LDM)
or a maximum-tolerated dose (MTD) schedule (Online
Resource 1). This led to the establishment of 6 BMH29L
subclones: Ctrl-LDM, Ctrl-MTD, VLB-LDM, VLB-MTD,
VP16-LDM and VP16-MTD. The impact of repeated expo-
sure to chemotherapy on the doubling time of these sub-
clones was determined by proliferation assay (Fig. 1a).
BMH29L cells treated fortnightly with vinblastine at high
concentration (VLB-MTD) proliferated at a faster rate as
compared to control cells (22.9 ± 1.1 h and 27.5 ± 2.5 h
for VLB-MTD and Ctrl-MTD cells, respectively; p \ 0.05).
In contrast, BMH29L cells treated 5 days a week with eto-
poside at low concentration (VP16-LDM) had a significantly
slower doubling time as compared to control cells
(36.0 ± 2.1 h and 29.7 ± 2.6 h for VP16-LDM and Ctrl-
LDM cells, respectively; p \ 0.05). Furthermore, repeated
exposure to LDM chemotherapy resulted in a significantly
slower doubling time of endothelial cells as compared to
MTD chemotherapy (p \ 0.01).
Matrigel assay was then used to analyse the effects of
long-term chemotherapy treatment on the capacity of
endothelial cells to undergo morphological differentiation
into vascular structures in vitro (Fig. 1b). Repeated expo-
sure to etoposide resulted in impaired angiogenic proper-
ties, irrespective of the treatment schedule (-33 and
-39 % vessel formation for VP16-LDM and VP16-MTD
cells as compared to control cells, respectively; p \ 0.05).
In contrast, the impact of vinblastine on the angiogenic
potential of endothelial cells was schedule-dependent.
VLB-LDM cells displayed impaired angiogenic properties
(-20 % as compared to control cells; p \ 0.05) whereas
VLB-MTD cells were able to form vascular structures to the
same extent as control untreated cells.
Conventional and metronomic chemotherapy
differentially impact on the chemosensitivity
of vascular endothelial cells
Short-term growth inhibition assay with vinblastine, eto-
poside and paclitaxel (PTX) was used to determine whether
repeated exposure to chemotherapy could result in acquisi-
tion of drug resistance in vascular endothelial cells. We
found that the long-term effects of chemotherapy on the
chemosensitivity of endothelial cells were schedule-
376 Angiogenesis (2013) 16:373–386
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dependent (Fig. 2). While repeated exposure to vinblastine
at MTD increased the resistance of BMH29L to paclitaxel
by 76 % as compared to control untreated cells (Fig. 2c;
p \ 0.05), repeated exposure to LDM chemotherapy did not
induce resistance but rather increased the chemosensitivity
of endothelial cells. VLB-LDM cells were found to have a
41 % increase in sensitivity to etoposide (Fig. 2b; p \ 0.05)
and VP16-LDM cells a 51, 57 and 40 % increase in sensi-
tivity to vinblastine (Fig. 2a; p \ 0.001), etoposide (Fig. 2b;
p \ 0.01) and paclitaxel (Fig. 2c; p \ 0.05) as compared to
control cells, respectively. In addition, except for repeated
exposure to etoposide, which resulted in increased sensi-
tivity to etoposide irrespective of the treatment schedule,
long-term treatment with LDM chemotherapy increased the
overall drug sensitivity of endothelial cells as compared to
cells exposed to MTD chemotherapy (Fig. 2a–c; p \ 0.05).
Angiogenesis assay further confirmed these results.
Repeated exposure to etoposide resulted in increased sen-
sitivity to the anti-angiogenic effects of vinblastine (Fig. 2d;
p \ 0.01), etoposide (Fig. 2e; p \ 0.05) and paclitaxel
(Fig. 2f; p \ 0.05), irrespective of the treatment schedule.
Long-term effects of vinblastine however were schedule-
dependent. Repeated exposure to vinblastine at MTD did not
affect the sensitivity of endothelial cells to the anti-angio-
genic activity of chemotherapeutic drugs whereas repeated
exposure to vinblastine at low concentration significantly
increased sensitivity (Fig. 2d–f; p \ 0.05).
Repeated exposure to chemotherapy modulates
the expression of ABC transporter without dramatically
affecting intracellular drug accumulation
To gain insights into the mechanisms involved in the dif-
ferential chemosensitivity of endothelial cells following
repeated exposure to chemotherapy, the gene expression
level of ATP-binding cassette (ABC) transporters was
assessed using quantitative real-time RT-PCR. Our results
showed that long-term treatment with chemotherapy
resulted in a significant increase (2.6- to 10.6-fold increase
as compared to control untreated cells; p \ 0.05) in ABCB1
Fig. 1 Impact of repeated
exposure to chemotherapy on
the angiogenic potential of
endothelial cells. a Doubling
time of the 6 endothelial
subclones established by
incubating BMH29L
endothelial cells for 100 days
with no drug (Ctrl-LDM and
Ctrl-MTD) or with vinblastine
(VLB) or etoposide (VP16)
following a low-dose
metronomic (LDM) schedule
(i.e. treatment 5 days/week with
highest non-toxic concentration)
or a maximum tolerated dose
(MTD) schedule (i.e. treatment
every 2 weeks with IC80).
Columns means of four
individual experiments, bars
SE. Statistics were calculated by
comparing drug-treated cells
with control untreated cells,
unless indicated otherwise;
*p \ 0.05; **p \ 0.01.
b Representative photographs of
the 6 BMH29L subclones
following 8 h incubation on
Matrigel. Vascular structures
were imaged on a Zeiss
Axiovert 200 M using a 5X
objective. Percentage of
angiogenesis inhibition as
compared to control cells is
indicated; NS non-significant,
Scale bar 250 lm
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expression—the gene encoding the P-glycoprotein (P-
gp)—irrespective of the treatment schedule (Fig. 3a). The
increase in P-gp expression was confirmed at the protein
level by immunoblotting (data not shown). In contrast, the
effect of chemotherapy on ABCC2 expression was sche-
dule-dependent. VLB-MTD cells showed a significant
increase in ABCC2 expression (4.1-fold as compared to
Ctrl-MTD cells; p \ 0.05) whereas both subclones treated
with LDM chemotherapy, VLB-LDM and VP16-LDM,
displayed decreased levels of ABCC2 (-73 and -62 % as
compared to control cells, respectively; p \ 0.05). No
significant change in the expression of ABCC1 and
ABCC10 was observed across the 6 BMH29L subclones.
Radiolabelled drug uptake studies were then performed
to determine whether the changes in ABCB1 and ABCC2
gene expression were functional and associated with
altered intracellular accumulation of the P-gp and ABCC2
substrate, vincristine. Our results showed that repeated
exposure to chemotherapy only marginally altered the
intracellular accumulation of tritiated vincristine ([3H]-
VCR) in endothelial cells (Fig. 3b). Repeated treatment
with etoposide thus led to a slight decrease in [3H]-VCR
uptake (-11 and -9 % for VP16-LDM and VP16-MTD as
compared to control cells; p \ 0.06) whereas repeated
exposure to vinblastine did not. Furthermore, the addition
of P-gp inhibitor, verapamil, did not significantly increase
[3H]-VCR uptake in the BMH29L subclones, with the
exception of a 7 % increase observed in VP16-MTD cells
(p \ 0.05). This is in marked contrast with the 234 %
increase in [3H]-VCR uptake induced by verapamil in P-gp
expressing neuroblastoma cells [32]. Our results thus
demonstrated that the increase in ABCB1 gene expression
Fig. 2 Impact of repeated exposure to chemotherapy on the chemo-
sensitivity of endothelial cells. a–c Histograms showing the IC50
values of vinblastine (a), etoposide (b) and paclitaxel (c) in the 6
BMH29L subclones as determined by 72 h growth inhibition assay.
d–f Percentage of vascular structure formation following 8 h
incubation on Matrigel with 5 nM vinblastine (d), 10 lM etoposide
(e) and 10 nM paclitaxel (f). Columns means of at least four
individual experiments, bars SE. Statistics were calculated by
comparing drug-treated cells with control cells, unless indicated
otherwise; *p \ 0.05; **p \ 0.01; ***p \ 0.001
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observed following repeated exposure to chemotherapy did
not translate into an increase in P-gp activity.
Repeated exposure to chemotherapy induces significant
changes in b-tubulin isotype expression
Our previous work and that of others have shown that
changes in the expression level of specific b-tubulin iso-
types can modulate the chemosensitivity of cancer cells not
only to microtubule-targeting agents but also to other
classes of chemotherapeutic drugs, such as DNA-damaging
agents (reviewed in [33]). In order to gain better insights
into how repeated exposure to chemotherapy affect the
angiogenic potential and chemosensitivity of endothelial
cells, the expression level of b-tubulin isotypes was
assessed in the 6 BMH29L subclones by western blotting
(Fig. 4). No significant difference in protein expression of
bI-, bIV- and total b-tubulin was observed across the 6
subclones. However, a 40 ± 1 % decrease in bIII-tubulin
protein expression was observed in VLB-LDM, VP16-LDM
and VP16-MTD cells as compared to control cells
(p \ 0.05). In addition, these cells also displayed a
21 ± 2 % decrease in bII-tubulin protein expression as
compared to control cells (p \ 0.05). The decrease in bII
and bIII-tubulin protein expression was associated with a
significant decrease in TUBB2A and TUBB3 (i.e. the genes
encoding bII- and bIII-tubulin, respectively) mRNA levels
in VLB-LDM and VP16-MTD cells (Online Resource 2),
suggesting that the repression occurred at the transcrip-
tional level. Collectively, these results show that repeated
exposure to chemotherapy, especially when administered
following a LDM schedule, resulted in the down-regulation
of specific tubulin isotypes in vascular endothelial cells.
bIII-tubulin expression mediates the sensitivity
of endothelial cells to the anti-angiogenic effects
of chemotherapy
To evaluate the implication of bII- and bIII-tubulin
expression in the modulation of the angiogenic potential
and chemosensitivity of endothelial cells following repe-
ated exposure to chemotherapy, functional analysis using
small interfering RNA (siRNA) was undertaken. HMEC-1
microvascular endothelial cells were transfected with siR-
NA targeting bII- and bIII-tubulin expression. After 72 h
incubation, this resulted in a 92 and 77 % decrease in bII-
and bIII-tubulin protein expression, respectively, without
any significant compensatory effect on the expression of
other tubulin isotypes (Fig. 5a; p \ 0.001). Knocking-
down bII- or bIII-tubulin expression had no effect on the
proliferation rate of endothelial cells or the organisation of
the tubulin cytoskeleton (data not shown). However,
silencing bIII-tubulin expression, but not bII-tubulin,
decreased by 18 % the capacity of HMEC-1 cells to form
capillary-like tubes on MatrigelTM in vitro (Figs. 5b, 6a,
top panel; p \ 0.001). This suggests that bIII-tubulin is, at
least in part, involved in the morphological differentiation
of endothelial cells into vascular structures.
Short-term growth inhibition assay then showed that
silencing bII- or bIII-tubulin expression only marginally
increased, if at all, the sensitivity of endothelial cells to the
anti-proliferative effects of chemotherapy agents. This lack
of sensitization was observed with vinblastine (Fig. 5c),
etoposide (Fig. 5d), paclitaxel (Fig. 5d), 2-methoxyestradiol
(2ME2, Fig. 5e), and other chemotherapeutic drugs such as
2ME2 analogue ENMD-1198 and mafosfamide (MFA)—an
analogue of cyclophosphamide active in vitro—(data not
shown). In contrast with the lack of effect on proliferation
inhibition, silencing bIII-tubulin expression, but not
Fig. 3 Impact of repeated exposure to chemotherapy on ABC
transporter expression and intracellular drug accumulation. a Relative
gene expression of ABC transporters as determined by qRT-PCR
using HPRT1 as control gene. b Accumulation of [3H]-VCR after 4 h
incubation in presence or absence of 10 lM verapamil. The BE(2)-C
neuroblastoma cell line expressing high levels of P-gp was included
as a positive control. Columns means of four individual experiments,
bars SE. Statistics were calculated by comparing drug-treated cells
with control cells, unless indicated otherwise; #p = 0.06; *p \ 0.05;
**p \ 0.01; ***p \ 0.001
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bII-tubulin, significantly increased the sensitivity of endo-
thelial cells to the anti-angiogenic effects of chemotherapy.
Incubation with 2 nM vinblastine inhibited vessel formation
by 15 and 13 % in control siRNA- and bII-tubulin siRNA-
treated HMEC-1 cells, respectively, while the same drug
treatment resulted in a 47 % angiogenesis inhibition in
bIII-tubulin siRNA-treated cells (Fig. 6a, middle panel;
p \ 0.05). Similarly, incubation with 5 lM etoposide
inhibited vessel formation by 35 % in bIII-tubulin siRNA-
treated HMEC-1 cells, as compared to 21 and 17 % in
control siRNA- and bII-tubulin siRNA-treated cells,
respectively (Fig. 6a, bottom panel; p \ 0.01). The sensiti-
zation of endothelial cells to the anti-angiogenic effects of
chemotherapy following bIII-tubulin knockdown was fur-
ther confirmed with other chemotherapy agents, such as
2-methoxyestradiol, paclitaxel and mafosfamide (Fig. 6b),
and using BMH29L cells transfected with siRNA (Online
Resource 3). Finally, bIII-tubulin knockdown was also
found to sensitize endothelial cells to the vascular-disrupting
activity of 2-methoxyestradiol analogue ENMD-1198
(Fig. 7). Incubation with ENMD-1198 at 0.25 lM for 2 h
resulted in 5–8 disruption marks per view field in the vas-
cular network formed by control and bII-tubulin siRNA-
treated HMEC-1 cells on Matrigel, whereas the same drug
treatment resulted in 10–15 disruption marks in the vascular
network formed by bIII-tubulin siRNA-treated cells
(Fig. 7a; p \ 0.001). Quantitative analysis of vascular dis-
ruption showed that a significant difference was observed
across a range of ENMD-1198 concentrations (0.1–2 lM;
Fig. 7b). Collectively, our results demonstrate that bIII-
tubulin expression is a determining factor in the anti-vas-
cular activity of chemotherapy agents.
Discussion
Inhibition of tumour angiogenesis is a recognized mecha-
nism of action of chemotherapy [2, 3, 34]. However, the
long-term effects of chemotherapeutic drugs on vascular
endothelial cells have not been explored. In this study, we
used bone-marrow derived endothelial cells immortalized
by ectopic expression of human telomerase reverse trans-
criptase [21] to analyse the impact of repeated exposure to
chemotherapy on the angiogenic potential and chemosen-
sitivity of vascular endothelial cells. We found that the
long-term effects of chemotherapy on endothelial cells
were drug-, concentration- and schedule-dependent.
First, we demonstrated that repeated exposure to vin-
blastine at the maximum-tolerated dose (MTD) increased
the angiogenic potential of vascular endothelial cells by
promoting their proliferation without altering their capacity
to form vascular structures on Matrigel. Furthermore, this
Fig. 4 Effect of repeated
exposure to chemotherapy on
the expression of b-tubulin
isotypes in endothelial cells.
a Representative immunoblots
of total endothelial cell lysates
following long-term treatment
with chemotherapy. Membranes
were probed with antibodies
directed against GADPH
(loading control), bI-, bII-,
bIII-, bIV- and total b-tubulin.
b Histogram showing the
relative expression of tubulin
isotypes in the 6 BMH29L
subclones as determined by
densitometry after
normalization with GADPH.
Columns means of three
individual experiments, bars
SE. Statistics were calculated by
comparing drug-treated cells
with control cells; *p \ 0.05;
**p \ 0.01
380 Angiogenesis (2013) 16:373–386
123
treatment regimen led to a 1.8-fold increase in paclitaxel
resistance in endothelial cells. Recently, VEGF was found to
increase resistance to paclitaxel in tumour endothelial cells
by inducing ABCB1 expression [18]. Previous studies have
also reported that endothelial cells isolated from tumour
tissues, such as hepatocellular carcinoma [16] and malignant
glioma [17], displayed increased angiogenic potential and
intrinsic drug resistance, which may limit the effectiveness
of chemotherapy. Here, we provide the first evidence that
endothelial cells can acquire some level of drug resistance as
a result of repeated exposure to chemotherapy in vitro and
may contribute to drug resistance acquisition in tumours
in vivo following MTD chemotherapy. Further investiga-
tions are currently underway to validate our findings in vivo.
The increase in angiogenic potential and drug resistance
induced by MTD chemotherapy was in marked contrast
with the long-term effects of low-dose metronomic (LDM)
chemotherapy. Indeed, our results demonstrated that repe-
ated exposure to LDM chemotherapy led to sustained
impairment of the angiogenic potential of endothelial cells
and significantly increased their chemosensitivity. Cells
treated with LDM chemotherapy thus exhibited a slower
proliferation rate, decreased capacity to form vascular
structures on Matrigel and increased sensitivity to the anti-
proliferative and anti-angiogenic effects of chemotherapy
agents.
Our findings are in accordance with previous studies
showing that the presence and length of treatment-free
Fig. 5 Functional study of bII-
and bIII-tubulin in endothelial
cells. a Representative
immunoblots of whole cell
lysates, 72 h after transfection
of HMEC-1 cells with negative
control, bII- and bIII-tubulin
siRNA. Membranes were
probed with antibodies directed
against GADPH (loading
control), bI-, bII-, bIII- and
bIV-tubulin. b Mean surface
occupied by vascular structures
formed by HMEC-1 cells 72 h
after siRNA transfection and
following 8 h incubation on
Matrigel. Boxes min–max range
of at least 6 individual
experiments, bars SD;
***p \ 0.001. c–f Growth
inhibition assays performed on
siRNA-transfected HMEC-1
cells using Alamar Blue after
72 h incubation with a range of
concentrations of vinblastine
(c), etoposide (d), paclitaxel
(e) and 2-methoxyestradiol (f).
Points % of cell proliferation as
compared to untreated control
cells, means of at least three
individual experiments, bars
SE; log scale for x axis
Angiogenesis (2013) 16:373–386 381
123
intervals are major determinants in the development of
drug resistance in tumour cells, and that drug resistance
acquisition can be hindered, prevented and even circum-
vented simply by modifying the dose and schedule of
chemotherapy administration [1, 19, 20]. In the seminal
study that led to the development of metronomic chemo-
therapy, Browder et al. demonstrated that using more fre-
quent cyclophosphamide administration could re-sensitize
Lewis lung carcinoma tumours that were made resistant to
the same drug [1]. More recently, cyclophosphamide was
found to generate dramatically different resistance pheno-
types in prostate and breast cancer cells in vivo, depending
on the dose and schedule of treatment [20]. While cancer
cells made resistant to MTD cyclophosphamide in vivo
showed stable drug resistance in vitro and in vivo, cells
made resistant to LDM cyclophosphamide in vivo retained
sensitivity to chemotherapy agents in vitro and to MTD
cyclophosphamide in vivo. Here, we report differential
effects of vinblastine in endothelial cells when adminis-
tered at the MTD or following a LDM schedule, similar to
that observed with taxanes and cyclophosphamide in
tumour cells. In contrast, the effects of etoposide appeared
to be less schedule-dependent in endothelial cells and
repeated exposure led to impaired angiogenic potential and
Fig. 6 Impact of bII- and bIII-
tubulin knockdown on the
sensitivity of endothelial cells to




incubated for 8 h on Matrigel in
the absence of drug (top panel)
or in presence of vinblastine at
2 nM (middle panel) and
etoposide at 5 lM (bottom
panel). Vascular structures were
imaged on a Zeiss Axiovert
200 M using a 5X objective.
Percentage of angiogenesis
inhibition as compared to
untreated control siRNA-
transfected cells is indicated;
NS non-significant, scale bar
250 lm. b Percentage of
vascular structure formation by
siRNA-transfected HMEC-1
cells following 8 h incubation
on Matrigel with 2 nM
vinblastine (VLB), 2 lM
2-methoxyestradiol (2ME2),
5 nM paclitaxel (PTX), 5 lM
etoposide (VP16) and 10 lM
mafosfamide (MFA), as
compared to control untreated
cells. Columns means of at least
three individual experiments,
bars SE. Statistics were
calculated by comparing the
mean surface occupied by
closed vascular structures per
view field (at least 10 view
fields per condition); *p \ 0.05;
**p \ 0.01; ***p \ 0.001
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increased chemosensitivity, irrespective of the treatment
schedule.
Since intracellular drug accumulation is the basic
requirement for chemotherapy agents to exert their effects,
upregulation of ABC transporters is of crucial importance
in drug resistance acquisition [35]. Here we found that
repeated exposure to chemotherapy induced a significant
upregulation of ABCB1 gene expression, irrespective of the
treatment schedule and the type of chemotherapy agent
used. In contrast, the effects on ABCC2 gene expression
were schedule-dependent, with an increase observed in
VLB-MTD cells and a decrease in VLB-LDM and VP16-
LDM cells. However, the changes in ABC transporter gene
expression did not correlate with major changes in intra-
cellular drug accumulation. All 6 endothelial subclones
were found to accumulate very high levels of tritiated
vincristine (*45 pmol per mg of protein), which was two-
to six-fold higher than in neuroblastoma cells. This high
vincristine uptake was unaltered by co-administration of
verapamil, suggesting that the increase in ABCB1 gene
expression did not translate into increased drug efflux.
Interestingly, increased uptake of paclitaxel in endothelial
cells was previously reported and proposed as a potential
mechanism for the anti-angiogenic activity of paclitaxel
[36]. Here we demonstrated that endothelial uptake of
Vinca alkaloids is also high and may contribute to their
potent anti-vascular properties [37].
The lack of correlation between changes in ABC
transporter expression and intracellular drug accumulation
strongly suggests that the effects of repeated exposure to
chemotherapy on the drug sensitivity of endothelial cells
are not mediated by ABC transporters. We therefore
sought to investigate other candidate genes that may be
involved. The expression level of specific b-tubulin iso-
types has been shown to influence drug sensitivity in a
range of cancer cell lines and malignancies, including
lung, ovarian, breast and prostate cancers (reviewed in
[33]). Here we found that changes in chemosensitivity of
endothelial cells induced by repeated exposure to che-
motherapy were associated with significant changes in
b-tubulin isotype expression. In particular, all 3 BMH29L
subclones displaying increased drug sensitivity (VLB-
LDM, VP16-LDM and VP16-MTD) were found to express
lower protein levels of bII- and bIII-tubulin. This is the
Fig. 7 Impact of bII- and bIII-tubulin knockdown on the sensitivity
of endothelial cells to vascular-disrupting agent ENMD-1198. a Rep-
resentative photographs of siRNA-transfected HMEC-1 cells in
vascular-disruption assay. Cells were first allowed to form vascular
structures on Matrigel for 6 h before drug treatment was initiated.
Cells were then incubated for 2 h in presence of ENMD-1198 at
0.25 lM and vascular structures were imaged on a Zeiss Axiovert
200 M using a 5X objective. Arrows point to collapsing and
regressing vascular structures. Percentage of vascular disruption is
indicated; Scale bar 250 lm. b Dose-dependent effect of ENMD-
1198 on the disruption of capillary-like structures formed by siRNA-
transfected HMEC-1 cells, after 2 h drug incubation. Points % of
intact vascular structures as compared to untreated control cells,
means of at least three individual experiments, bars SE; log scale for
x axis. Statistics were calculated by comparing the mean surface
occupied by closed vascular structures per view field (at least 10 view
fields per condition); *p \ 0.05; ***p \ 0.001
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first demonstration that repeated exposure to microtubule-
targeting agents, such as vinblastine, and other classes of
chemotherapy agent, such as the topoisomerase inhibitor
etoposide, can result in significant changes in tubulin
isotype expression in non-cancer cells, most likely
through transcriptional repression.
Using a series of elegant experiments, Piquette-Miller
and colleagues demonstrated that continuous administra-
tion of taxanes (i.e. paclitaxel and docetaxel) was consid-
erably more efficacious than intermittent taxane therapy
(i.e. once or thrice weekly) against ovarian cancer cells
in vitro and in vivo [19, 38, 39]. Interestingly, intermittent
docetaxel treatment of ovarian tumours led to significant
upregulation of ABCB1, ABCC10, bcl2 and TUBB3 among
other genes involved in drug resistance whereas continuous
docetaxel did not induce upregulation of any analysed
genes but instead led to a downregulation of ABCC10,
TUBB3 and stathmin [19]. Our results are in accordance
with these studies and confirm the influence of treatment
schedule on the modulation of the expression of genes
involved in drug resistance not only in tumour cells but
also in endothelial cells.
We previously reported relatively high expression of
bII- and bIII-tubulin in vascular endothelial cells [40] and
showed that both these tubulin isotypes strongly influence
the response of non-small cell lung carcinoma cells
(NSCLC) to chemotherapeutic drugs [25, 28, 29, 41]. In
the present study, functional analysis using gene silencing
technology showed that bIII-tubulin, but not bII-tubulin,
plays a crucial role in the anti-angiogenic activity of che-
motherapy. Knocking down bIII-tubulin expression thus
resulted in a small, but significant, decrease in the angio-
genic potential of endothelial cells and increased their
sensitivity to the anti-angiogenic and vascular-disrupting
activity of chemotherapeutic drugs. This finding provides
further evidence of the key role played by bIII-tubulin in
tumour progression, angiogenesis and drug resistance.
Recently, bIII-tubulin was identified as a marker of
angiogenic perivascular cells in rat mesenteric tissues
during active capillary sprouting [42]. Furthermore, a large
number of studies have linked abnormal or high levels of
bIII-tubulin expression with more aggressive and drug-
resistant phenotypes in a range of tumour types, including
lung, ovarian, breast and gastric cancers (reviewed in [33,
43]). In NSCLC for instance, expression of bIII-tubulin is
associated with poorly differentiated tumour tissue, high-
grade malignancy and increased metastatic potential [43],
as well as lower response rate to paclitaxel/vinorelbine-
based chemotherapy and shorter progression-free and
overall survival [44, 45]. Collectively the results of our
current study together with our previous work [25, 28, 29,
41] and accumulating clinical data strongly suggest that
bIII-tubulin represents an attractive therapeutic target to
increase the anti-angiogenic effects of chemotherapy and
overall anti-tumour efficacy.
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